arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Arcadia Biosciences, Inc.

RKDA
$0.36 ▼ -0.09 (-20.13%) at close
Energy ·Crude Petroleum & Natural Gas ·USCrude Petroleum & Natural Gas
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcadia Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -3.7% ↘
Op. Margin -51.5% ↗
ROIC None
FCF / Share $-3.46 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.86M
↓ -3.7% —
Net Income Profit after all expenses
$-2.34M
↑ +66.8% —
Operating Margin Operating profit as % of sales
-51.5%
↑ +28.8% 5th
FCF / Share Free cash flow per share
$-3.46
↑ +51.0% —
Long-Term Debt Long-term obligations
$3.25M
↑ +2933.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Cash Quality ↑
86

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 51 quarters